The aim of this review was to survey the literature on depression in patients with myocardial infarction to assess the methodological quality and to test whether depression leads to an increased postmyocardial infarction mortality. Medline, Psycinfo, and www.UMI.com were searched, and researchers were contacted in the autumn of 2003. Thirty-one articles were reviewed. Only seven articles scored above a predefined level of 75% for acceptable quality. The articles lack description of non-responders, recall period for depressive symptoms, validation of applied instrument on target population, and sample size large enough to show differences between groups. The prevalence rates of depression ranged from 1.6 to 50%. In eight articles, a diagnostic test was applied, in the rest of the studies, questionnaires were used. The prevalence of depression was highest in those using patient-completed questionnaires. A significant positive association was shown between depression and postmyocardial infarction mortality in 15 studies, a non-significant association in 14, and in two articles, this was not reported. In articles with data collection starting after 1994, a non-significant relation tended to be reported. The studies were generally not of acceptable quality. They lacked sufficient power to show differences in stated end points between groups. Application of non-validated instruments caused large differences in prevalence rates of depression. Future studies should include a minimum of 1,000 patients, use a validated instrument, re-examine the patients, and describe participants and non-participants in detail.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000083165 | DOI Listing |
Pharmacoecon Open
January 2025
Optimax Access Ltd, Kenneth Dibben House, Enterprise Rd, Chilworth, Southampton University Science Park, Southampton, UK.
Background: Patients with a left ventricular ejection fraction ≤ 35% are at increased risk of sudden cardiac death (SCD) within the first months after a myocardial infarction (MI). The wearable cardioverter defibrillator (WCD) is an established, safe and effective solution which can protect patients from SCD during the first months after an MI, when the risk of SCD is at its peak. This study aimed to evaluate the cost-effectiveness of WCD combined with guideline-directed medical therapy (GDMT) compared to GDMT alone, after MI in the English National Health Service (NHS).
View Article and Find Full Text PDFNPJ Regen Med
January 2025
Department of Cardiovascular Surgery, Université Paris Cité, INSERM U970, PARCC Hôpital Européen Georges Pompidou, 75015, Paris, France.
Myocardial infarction (MI) causes the loss of millions of cardiomyocytes, and current treatments do not address this root issue. New therapies focus on stimulating cardiomyocyte division in the adult heart, inspired by the regenerative capacities of lower vertebrates and neonatal mice. This review explores strategies for heart regeneration, offers insights into cardiomyocyte proliferation, evaluates in vivo models, and discusses integrating in vitro human cardiac models to advance cardiac regeneration research.
View Article and Find Full Text PDFFront Cardiovasc Med
January 2025
Department of Cardiology, Liuzhou Workers' Hospital, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, China.
Background: Fibroblasts in the fibrotic heart exhibit a heterogeneous biological behavior. The specific subsets of fibroblasts that contribute to progressive cardiac fibrosis remain unrevealed. Our aim is to identify the heart fibroblast (FB) subsets that most significantly promote fibrosis and the related critical genes as biomarkers for ischemic heart disease.
View Article and Find Full Text PDFFront Cardiovasc Med
January 2025
Department of Cardiology, Shibei Hospital of Jing'an District, Shanghai, China.
Objective: To investigate the effects of dapagliflozin, in addition to standard therapy, on heart rate variability (HRV), soluble growth stimulation expressed gene 2 protein (sST2), N-terminal pro B-type natriuretic peptide (NT-proBNP), and echocardiographic parameters in patients with early-onset post-myocardial infarction heart failure (HF).
Methods: A total of 98 patients with early-onset post-myocardial infarction HF were enrolled and randomly divided into a control group ( = 48, receiving standard therapy) and an observation group ( = 50, receiving standard therapy plus dapagliflozin 10 mg daily). HRV, cardiac function, and echocardiographic parameters were measured at baseline and after 24 weeks of treatment.
Int J Nanomedicine
January 2025
Department of Emergency and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Purpose: Cardiac fibrosis, a key contributor to ventricular pathologic remodeling and heart failure, currently lacks effective therapeutic approaches.
Patients And Methods: Small extracellular vesicles from young healthy human plasma (Young-sEVs) were characterized via protein marker, transmission electron microscopy, and nanoparticle tracking analysis, then applied in cellular models and mouse models of cardiac fibrosis. Western blotting and qRT-PCR were used to identify protective signaling pathways in cardiac fibroblasts (CFs).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!